NO20070893L - Hydantoinderivater for behandling av inflammasjonslidelser. - Google Patents
Hydantoinderivater for behandling av inflammasjonslidelser.Info
- Publication number
- NO20070893L NO20070893L NO20070893A NO20070893A NO20070893L NO 20070893 L NO20070893 L NO 20070893L NO 20070893 A NO20070893 A NO 20070893A NO 20070893 A NO20070893 A NO 20070893A NO 20070893 L NO20070893 L NO 20070893L
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- inflammatory disorders
- hydantoin derivatives
- hydantoin
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
Abstract
Forbindelser med formel (I) eller et farmasøytisk akseptabelt salt eller solvat eller en isomer av denne, kan være nyttige for behandling av sykdommer eller tilstander formidlet av MMP, ADAM, TACE, TNF-a eller kombinasjoner av disse.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58850204P | 2004-07-16 | 2004-07-16 | |
PCT/US2005/024771 WO2006019768A1 (en) | 2004-07-16 | 2005-07-13 | Hydantoin derivatives for the treatment of inflammatory disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20070893L true NO20070893L (no) | 2007-04-13 |
Family
ID=35134266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20070893A NO20070893L (no) | 2004-07-16 | 2007-02-16 | Hydantoinderivater for behandling av inflammasjonslidelser. |
Country Status (21)
Country | Link |
---|---|
US (2) | US7482370B2 (no) |
EP (1) | EP1778676B1 (no) |
JP (1) | JP4943327B2 (no) |
KR (1) | KR20070032787A (no) |
CN (1) | CN101018782A (no) |
AR (1) | AR050169A1 (no) |
AT (1) | ATE478864T1 (no) |
AU (1) | AU2005275213A1 (no) |
BR (1) | BRPI0513433A (no) |
CA (1) | CA2573764A1 (no) |
DE (1) | DE602005023172D1 (no) |
EC (1) | ECSP077163A (no) |
ES (1) | ES2349041T3 (no) |
IL (1) | IL180736A0 (no) |
MX (1) | MX2007000668A (no) |
NO (1) | NO20070893L (no) |
PE (1) | PE20060561A1 (no) |
RU (1) | RU2007105685A (no) |
TW (1) | TWI297269B (no) |
WO (1) | WO2006019768A1 (no) |
ZA (1) | ZA200700384B (no) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7488745B2 (en) | 2004-07-16 | 2009-02-10 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
US7504424B2 (en) * | 2004-07-16 | 2009-03-17 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
JP4943327B2 (ja) | 2004-07-16 | 2012-05-30 | シェーリング コーポレイション | 炎症性障害の処置のためのヒダントイン誘導体 |
US7879997B2 (en) * | 2005-08-12 | 2011-02-01 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
PE20071240A1 (es) | 2006-01-17 | 2008-01-14 | Schering Corp | Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios |
AU2007240568A1 (en) * | 2006-04-21 | 2007-11-01 | Amgen Inc. | Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use |
DE102006037478A1 (de) | 2006-08-10 | 2008-02-14 | Merck Patent Gmbh | 2-(Heterocyclylbenzyl)-pyridazinonderivate |
JP2010502617A (ja) | 2006-08-31 | 2010-01-28 | シェーリング コーポレイション | 抗菌物質として有用なヒダントイン誘導体 |
DE102007038957A1 (de) | 2007-08-17 | 2009-02-19 | Merck Patent Gmbh | 6-Thioxo-pyridazinderivate |
US8314131B2 (en) | 2007-09-21 | 2012-11-20 | Amgen Inc. | Triazole fused heteroaryl compounds and methods of use thereof |
WO2010036638A2 (en) * | 2008-09-24 | 2010-04-01 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
TW201024303A (en) | 2008-09-24 | 2010-07-01 | Schering Corp | Compounds for the treatment of inflammatory disorders |
WO2010054279A1 (en) * | 2008-11-10 | 2010-05-14 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
US8569336B2 (en) | 2008-11-10 | 2013-10-29 | Ling Tong | Compounds for the treatment of inflammatory disorders |
LT3202460T (lt) | 2010-02-11 | 2019-10-10 | Celgene Corporation | Arilmetoksi izoindolino dariniai ir kompozicijos, apimantys ir jų panaudojimo būdus |
ES2592154T3 (es) | 2010-07-08 | 2016-11-28 | Kaken Pharmaceutical Co., Ltd. | Derivado de N-hidroxiformamida y medicamento que contiene el mismo |
US20150232455A1 (en) * | 2010-12-15 | 2015-08-20 | Allan C. Krueger | Anti-viral compounds |
ES2663246T3 (es) * | 2011-12-09 | 2018-04-11 | Kaken Pharmaceutical Co., Ltd. | Derivado de piridona y medicamento que lo contiene |
WO2013129622A1 (ja) | 2012-03-02 | 2013-09-06 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
US9556169B2 (en) * | 2012-11-19 | 2017-01-31 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
WO2014077401A1 (ja) * | 2012-11-19 | 2014-05-22 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
WO2014122474A1 (en) | 2013-02-07 | 2014-08-14 | Takeda Pharmaceutical Company Limited | Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists |
EP3006437B1 (en) | 2013-06-07 | 2020-08-05 | Kaken Pharmaceutical Co., Ltd. | (+)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2h)-yl)methyl]imidazolidine-2,4-dione and drug containing same |
JP2017501145A (ja) | 2013-12-23 | 2017-01-12 | ノージン ビーブイ | Ccr9調節因子として有用な化合物 |
US9763992B2 (en) | 2014-02-13 | 2017-09-19 | Father Flanagan's Boys' Home | Treatment of noise induced hearing loss |
MD3344248T2 (ro) | 2015-09-02 | 2022-10-31 | Trevena Inc | Aza-heterociclic cu 6 elemente conținând compuși de modulare a receptorului delta-opioid, metode de utilizare și fabricare a acestora |
ES2781309T3 (es) * | 2016-05-27 | 2020-09-01 | Bristol Myers Squibb Co | Triazolonas y tetrazolonas como inhibidores de ROCK |
CN108069942A (zh) * | 2016-11-10 | 2018-05-25 | 四川大学 | 苯酞吡唑酮类偶联物、其制备方法和用途 |
EP3582783B1 (en) | 2017-02-17 | 2023-06-07 | Trevena, Inc. | 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same |
US11702408B2 (en) | 2017-02-17 | 2023-07-18 | Trevena, Inc. | 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same |
US20210017174A1 (en) | 2018-03-07 | 2021-01-21 | Bayer Aktiengesellschaft | Identification and use of erk5 inhibitor |
EP3917935A4 (en) * | 2019-01-30 | 2022-11-16 | Avista Pharma Solutions, Inc. | SYNTHESIS PROCESS AND NEW INTERMEDIATES |
BR112022009131A2 (pt) * | 2019-11-14 | 2022-07-26 | Foresee Pharmaceuticals Co Ltd | Inibidores de metaloproteinase de matriz (mmp) e métodos de uso dos mesmos |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4110536A (en) * | 1977-04-18 | 1978-08-29 | Miles Laboratories, Inc. | Derivatives of 5-(indol-3-yl)hydantoin |
CA2083891A1 (en) * | 1991-12-03 | 1993-06-04 | Angus Murray Macleod | Heterocyclic compounds, compositions containing them and their use in therapy |
US6228869B1 (en) | 1996-10-16 | 2001-05-08 | American Cyanamid Company | Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
TR199902124T2 (xx) * | 1997-03-03 | 2000-06-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | �ltihapl� hastal�klar�n tedavisinde yararl� k���k molek�ller. |
EP1210326B1 (en) | 1999-08-18 | 2004-02-25 | Warner-Lambert Company LLC | Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors |
WO2001070734A2 (en) | 2000-03-17 | 2001-09-27 | Bristol-Myers Squibb Pharma Company | Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha |
EE200300439A (et) | 2001-03-15 | 2003-12-15 | Astrazeneca Ab | Metalloproteinaasi inhibiitorid |
JP2004535411A (ja) | 2001-05-25 | 2004-11-25 | ブリストルーマイヤーズ スクイブ カンパニー | マトリックスメタロプロテナーゼ及び/またはTNF−α転換酵素(TACE)の阻害剤としてのヒダントイン及び関連複素環化合物 |
US6936620B2 (en) | 2001-12-20 | 2005-08-30 | Bristol Myers Squibb Company | Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases |
WO2003053941A2 (en) | 2001-12-20 | 2003-07-03 | Bristol-Myers Squibb Company | Barbituric acid derivatives as inhibitors of tnf-alpha converting enzyme (tace) and/or matrix metalloproteinases |
US7102008B2 (en) | 2002-08-01 | 2006-09-05 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme |
GB0221250D0 (en) | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Compounds |
GB0221246D0 (en) | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Compounds |
US7041693B2 (en) | 2002-10-04 | 2006-05-09 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
ATE443044T1 (de) | 2002-12-19 | 2009-10-15 | Vertex Pharma | Tace inhibitoren |
US7504424B2 (en) | 2004-07-16 | 2009-03-17 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
JP4943327B2 (ja) | 2004-07-16 | 2012-05-30 | シェーリング コーポレイション | 炎症性障害の処置のためのヒダントイン誘導体 |
US7488745B2 (en) | 2004-07-16 | 2009-02-10 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
PE20071240A1 (es) | 2006-01-17 | 2008-01-14 | Schering Corp | Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios |
JP2010502617A (ja) | 2006-08-31 | 2010-01-28 | シェーリング コーポレイション | 抗菌物質として有用なヒダントイン誘導体 |
-
2005
- 2005-07-13 JP JP2007521589A patent/JP4943327B2/ja not_active Expired - Fee Related
- 2005-07-13 ES ES05771446T patent/ES2349041T3/es active Active
- 2005-07-13 AR ARP050102901A patent/AR050169A1/es not_active Application Discontinuation
- 2005-07-13 EP EP05771446A patent/EP1778676B1/en active Active
- 2005-07-13 CN CNA2005800304595A patent/CN101018782A/zh active Pending
- 2005-07-13 KR KR1020077001084A patent/KR20070032787A/ko not_active Application Discontinuation
- 2005-07-13 MX MX2007000668A patent/MX2007000668A/es active IP Right Grant
- 2005-07-13 BR BRPI0513433-1A patent/BRPI0513433A/pt not_active IP Right Cessation
- 2005-07-13 AT AT05771446T patent/ATE478864T1/de not_active IP Right Cessation
- 2005-07-13 WO PCT/US2005/024771 patent/WO2006019768A1/en active Application Filing
- 2005-07-13 RU RU2007105685/04A patent/RU2007105685A/ru not_active Application Discontinuation
- 2005-07-13 DE DE602005023172T patent/DE602005023172D1/de active Active
- 2005-07-13 CA CA002573764A patent/CA2573764A1/en not_active Abandoned
- 2005-07-13 AU AU2005275213A patent/AU2005275213A1/en not_active Abandoned
- 2005-07-13 US US11/180,863 patent/US7482370B2/en active Active
- 2005-07-14 TW TW094123832A patent/TWI297269B/zh not_active IP Right Cessation
- 2005-07-14 PE PE2005000812A patent/PE20060561A1/es not_active Application Discontinuation
-
2007
- 2007-01-12 ZA ZA200700384A patent/ZA200700384B/xx unknown
- 2007-01-12 EC EC2007007163A patent/ECSP077163A/es unknown
- 2007-01-16 IL IL180736A patent/IL180736A0/en unknown
- 2007-02-16 NO NO20070893A patent/NO20070893L/no not_active Application Discontinuation
-
2008
- 2008-12-18 US US12/338,353 patent/US7683085B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20060205797A1 (en) | 2006-09-14 |
DE602005023172D1 (de) | 2010-10-07 |
US7683085B2 (en) | 2010-03-23 |
EP1778676A1 (en) | 2007-05-02 |
RU2007105685A (ru) | 2008-08-27 |
MX2007000668A (es) | 2007-03-08 |
PE20060561A1 (es) | 2006-07-13 |
WO2006019768A1 (en) | 2006-02-23 |
AU2005275213A1 (en) | 2006-02-23 |
ZA200700384B (en) | 2008-09-25 |
AR050169A1 (es) | 2006-10-04 |
KR20070032787A (ko) | 2007-03-22 |
EP1778676B1 (en) | 2010-08-25 |
ATE478864T1 (de) | 2010-09-15 |
US20090111803A1 (en) | 2009-04-30 |
CA2573764A1 (en) | 2006-02-23 |
TW200616620A (en) | 2006-06-01 |
BRPI0513433A (pt) | 2008-05-06 |
US7482370B2 (en) | 2009-01-27 |
ES2349041T3 (es) | 2010-12-22 |
JP4943327B2 (ja) | 2012-05-30 |
JP2008506692A (ja) | 2008-03-06 |
TWI297269B (en) | 2008-06-01 |
ECSP077163A (es) | 2007-02-28 |
IL180736A0 (en) | 2007-06-03 |
CN101018782A (zh) | 2007-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20070893L (no) | Hydantoinderivater for behandling av inflammasjonslidelser. | |
NO20083568L (no) | Hydantoinforbindelser for behandling av inflammatoriske forstyrrelser | |
NO20083561L (no) | Forbindelser for behandling av inflammatoriske forstyrrelser | |
TW200612911A (en) | Compounds for the treatment of inflammatory disorders | |
DK1471057T3 (da) | Pyrimidinyleddikesyrederivater, der er egnede til behandlingen af sygdomme medieret af CRTH2 | |
WO2007079199A3 (en) | Substituted bis-amide metalloprotease inhibitors | |
NO20062561L (no) | Kinoliner nyttige for behandling av kardiovaskulaere sykdommer | |
DK1778673T3 (da) | Nye hydantoin-derivater til behandling af obstruktive luftvejssygdomme | |
NO20092723L (no) | Indazolylester og amidderivater for behandling av gluccocorticoid reseptormedierte sykdommer | |
NO20056130L (no) | Nye substituerte 3-svovelindoler | |
EA200870292A1 (ru) | Соединения на основе имидазола, композиции, содержащие их, и способы их применения | |
MX2007003793A (es) | Antagonistas del receptor 2 de citocina quimioatrayente de dipiperidina sustituida. | |
NO20070855L (no) | Arylidener for behandling av estrogenrelaterte reseptor-alfamedierte sykdommer. | |
NO20032801L (no) | Tiazolderivater for behandling av PPAR-relaterte forstyrrelser | |
TW200640869A (en) | PGD2 receptor antagonists for the treatment of inflammatory diseases | |
EA200802213A1 (ru) | Способы лечения заболеваний крови | |
NO20080865L (no) | Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer | |
DE602005014621D1 (de) | 3-ä4-heterocyclyl-1,2,3-triazol-1-ylü-n-arylbenzamide als inhibitoren der cytokinenproduktion für die behandlung von chronischen entzündlichen erkrankungen | |
EA200401194A1 (ru) | Миметики глюкокортикоидов, способы их получения, фармацевтические композиции и их применение | |
NO20063928L (no) | Substituerte kinolinforbindelser | |
NO20083002L (no) | Fremgangsmate for anvendelse av CD40-bindende forbindelser | |
NO20063647L (no) | Nye inhibitorer av chymase | |
NO20054121L (no) | Benzopyranforbindelser anvendelige for behandling av inflammatoriske tilstander | |
NO20062021L (no) | Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika | |
NO20081133L (no) | Tieno[2,3-B]-pyridin-5-karbonitriler som protein kinase inhibitorer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |